Ascendis Gets EU Committee Backing for Pediatric Achondroplasia Drug
The CHMP recommended authorization of TransCon CNP, with a European Commission decision expected in the fourth quarter of 2026.
Makkler Newsroom · Oct 16, 07:54 PM · 1 min read
Market closed· · USD · Data may be delayed
Avg. target $316.22 (+14.8%)
Prices may be delayed and are for informational purposes only - not investment advice.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.